Literature DB >> 6810361

Demonstration of active tolerance in maintenance of established islet of Langerhans allografts.

D Faustman, V Hauptfeld, P Lacy, J Davie.   

Abstract

Streptozotocin-induced diabetes in mice can be reversed by transplantation of islets of Langerhans from histoincompatible mice if the islets are treated with anti-Ia-serum and complement before transplantation. Here we show that anti-Ia-treated islets most likely induce tolerance in the recipient animals. Daily injections of recipient-specific anti-I-J-serum (beginning 80 or more days after transplantation) and small numbers of donor splenocytes caused the prompt rejection of the islets in half of the animals; neither anti-I-J-serum nor donor splenocytes alone were effective. It is likely that rejection of established allografts after this treatment is the result of abolition of the activity of allograft-specific suppressor cells.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6810361      PMCID: PMC346595          DOI: 10.1073/pnas.79.13.4153

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

1.  Effect of idiotype-specific suppressor T cells on primary and secondary responses.

Authors:  F L Owen; A Nisonoff
Journal:  J Exp Med       Date:  1978-07-01       Impact factor: 14.307

Review 2.  Langerhans cells: a review of their nature with emphasis on their immunologic functions.

Authors:  I Silberberg-Sinakin; R L Baer; G J Thorbecke
Journal:  Prog Allergy       Date:  1978

3.  Method for the isolation of intact islets of Langerhans from the rat pancreas.

Authors:  P E Lacy; M Kostianovsky
Journal:  Diabetes       Date:  1967-01       Impact factor: 9.461

4.  New lymphocyte antigen system (Lna) controlled by the Ir region of the mouse H-2 complex.

Authors:  C S David; D C Shreffler; J A Frelinger
Journal:  Proc Natl Acad Sci U S A       Date:  1973-09       Impact factor: 11.205

5.  Potentiation of a primary in vivo antibody response by alloantisera against gene products of the I region of the H-2 complex.

Authors:  M Pierres; R N Germain; M E Dorf; B Benacerraf
Journal:  Proc Natl Acad Sci U S A       Date:  1977-09       Impact factor: 11.205

6.  Prolongation of murine islet allograft survival by pretreatment of islets with antibody directed to Ia determinants.

Authors:  D Faustman; V Hauptfeld; P Lacy; J Davie
Journal:  Proc Natl Acad Sci U S A       Date:  1981-08       Impact factor: 11.205

7.  Reduction of syngeneic tumor growth by an anti-I-J-alloantiserum.

Authors:  M I Greene; M E Dorf; M Pierres; B Benacerraf
Journal:  Proc Natl Acad Sci U S A       Date:  1977-11       Impact factor: 11.205

8.  A new I subregion (I-J) marked by a locus (Ia-4) controlling surface determinants on suppressor T lymphocytes.

Authors:  D B Murphy; L A Herzenberg; K Okumura; L A Herzenberg; H O McDevitt
Journal:  J Exp Med       Date:  1976-09-01       Impact factor: 14.307

9.  Ly and Ia antigen phenotypes of T cells involved in delayed-type hypersensitivity and in suppression.

Authors:  M A Vadas; J F Miller; I F McKenzie; S E Chism; F W Shen; E A Boyse; J R Gamble; A M Whitelaw
Journal:  J Exp Med       Date:  1976-07-01       Impact factor: 14.307

10.  T-cell regulation of antibody responses: demonstration of allotype-specific helper T cells and their specific removal by suppressor T cells.

Authors:  L A Herzenberg; K Okumura; H Cantor; V L Sato; F W Shen; E A Boyse; L A Herzenberg
Journal:  J Exp Med       Date:  1976-08-01       Impact factor: 14.307

View more
  3 in total

1.  Experimental immuno-alteration.

Authors:  P E Lacy
Journal:  World J Surg       Date:  1984-04       Impact factor: 3.352

2.  Theory and practice of immunoregulation by tissue treatment prior to transplantation.

Authors:  K J Lafferty; S J Prowse
Journal:  World J Surg       Date:  1984-04       Impact factor: 3.352

3.  Pancreatic islet transplantation--experimental experience and clinical potential.

Authors:  K J Lafferty
Journal:  West J Med       Date:  1985-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.